A genome-wide association study of survival in patients with sepsis
Background Sepsis is a severe systemic inflammatory response to infections that is accompanied by organ dysfunction and has a high mortality rate in adult intensive care units. Most genetic studies have identified gene variants associated with development and outcomes of sepsis focusing on biological candidates. We conducted the first genome-wide association study (GWAS) of 28-day survival in adult patients with sepsis. Methods This study was conducted in two stages. The first stage was performed on 687 European sepsis patients from the GEN-SEP network and 7.5 million imputed variants. Association testing was conducted with Cox regression models, adjusting by sex, age, and the main principal components of genetic variation. A second stage focusing on the prioritized genetic variants was performed on 2,063 ICU sepsis patients (1362 European Americans and 701 African-Americans) from the MESSI study. A meta-analysis of results from the two stages was conducted and significance was established at p < 5.0 × $ 10^{−8} $. Whole-blood transcriptomic, functional annotations, and sensitivity analyses were evaluated on the identified genes and variants. Findings We identified three independent low-frequency variants associated with reduced 28-day sepsis survival, including a missense variant in SAMD9 (hazard ratio [95% confidence interval] = 1.64 [1.37–6.78], p = 4.92 × $ 10^{−8} $). SAMD9 encodes a possible mediator of the inflammatory response to tissue injury. Interpretation We performed the first GWAS of 28-day sepsis survival and identified novel variants associated with reduced survival. Larger sample size studies are needed to better assess the genetic effects in sepsis survival and to validate the findings..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Critical care - 26(2022), 1 vom: 05. Nov. |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1186/s13054-022-04208-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2132624763 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2132624763 | ||
| 003 | DE-627 | ||
| 005 | 20240322062419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230506s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13054-022-04208-5 |2 doi | |
| 035 | |a (DE-627)OLC2132624763 | ||
| 035 | |a (DE-He213)s13054-022-04208-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Hernandez-Beeftink, Tamara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A genome-wide association study of survival in patients with sepsis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Background Sepsis is a severe systemic inflammatory response to infections that is accompanied by organ dysfunction and has a high mortality rate in adult intensive care units. Most genetic studies have identified gene variants associated with development and outcomes of sepsis focusing on biological candidates. We conducted the first genome-wide association study (GWAS) of 28-day survival in adult patients with sepsis. Methods This study was conducted in two stages. The first stage was performed on 687 European sepsis patients from the GEN-SEP network and 7.5 million imputed variants. Association testing was conducted with Cox regression models, adjusting by sex, age, and the main principal components of genetic variation. A second stage focusing on the prioritized genetic variants was performed on 2,063 ICU sepsis patients (1362 European Americans and 701 African-Americans) from the MESSI study. A meta-analysis of results from the two stages was conducted and significance was established at p < 5.0 × $ 10^{−8} $. Whole-blood transcriptomic, functional annotations, and sensitivity analyses were evaluated on the identified genes and variants. Findings We identified three independent low-frequency variants associated with reduced 28-day sepsis survival, including a missense variant in SAMD9 (hazard ratio [95% confidence interval] = 1.64 [1.37–6.78], p = 4.92 × $ 10^{−8} $). SAMD9 encodes a possible mediator of the inflammatory response to tissue injury. Interpretation We performed the first GWAS of 28-day sepsis survival and identified novel variants associated with reduced survival. Larger sample size studies are needed to better assess the genetic effects in sepsis survival and to validate the findings. | ||
| 650 | 4 | |a Sepsis | |
| 650 | 4 | |a Genome-wide association study | |
| 650 | 4 | |a Genomics | |
| 650 | 4 | |a 28 days | |
| 650 | 4 | |a Outcome | |
| 700 | 1 | |a Guillen-Guio, Beatriz |4 aut | |
| 700 | 1 | |a Lorenzo-Salazar, Jose M. |4 aut | |
| 700 | 1 | |a Corrales, Almudena |4 aut | |
| 700 | 1 | |a Suarez-Pajes, Eva |4 aut | |
| 700 | 1 | |a Feng, Rui |4 aut | |
| 700 | 1 | |a Rubio-Rodríguez, Luis A. |4 aut | |
| 700 | 1 | |a Paynton, Megan L. |4 aut | |
| 700 | 1 | |a Cruz, Raquel |4 aut | |
| 700 | 1 | |a García-Laorden, M. Isabel |4 aut | |
| 700 | 1 | |a Prieto-González, Miryam |4 aut | |
| 700 | 1 | |a Rodríguez-Pérez, Aurelio |4 aut | |
| 700 | 1 | |a Carriedo, Demetrio |4 aut | |
| 700 | 1 | |a Blanco, Jesús |4 aut | |
| 700 | 1 | |a Ambrós, Alfonso |4 aut | |
| 700 | 1 | |a González-Higueras, Elena |4 aut | |
| 700 | 1 | |a Espinosa, Elena |4 aut | |
| 700 | 1 | |a Muriel, Arturo |4 aut | |
| 700 | 1 | |a Tamayo, Eduardo |4 aut | |
| 700 | 1 | |a Martin, María M. |4 aut | |
| 700 | 1 | |a Lorente, Leonardo |4 aut | |
| 700 | 1 | |a Domínguez, David |4 aut | |
| 700 | 1 | |a de Lorenzo, Abelardo García |4 aut | |
| 700 | 1 | |a Giannini, Heather M. |4 aut | |
| 700 | 1 | |a Reilly, John P. |4 aut | |
| 700 | 1 | |a Jones, Tiffanie K. |4 aut | |
| 700 | 1 | |a Añón, José M. |4 aut | |
| 700 | 1 | |a Soro, Marina |4 aut | |
| 700 | 1 | |a Carracedo, Ángel |4 aut | |
| 700 | 1 | |a Wain, Louise V. |4 aut | |
| 700 | 1 | |a Meyer, Nuala J. |4 aut | |
| 700 | 1 | |a Villar, Jesús |4 aut | |
| 700 | 1 | |a Flores, Carlos |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care |d BioMed Central, 1997 |g 26(2022), 1 vom: 05. Nov. |h Online-Ressource |w (DE-627)331258269 |w (DE-600)2051256-9 |w (DE-576)279224680 |x 1466-609X |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:1 |g day:05 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13054-022-04208-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 936 | b | k | |a 44.00 |j Medizin: Allgemeines |j Medizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 1 |b 05 |c 11 | ||